혈관부종 치료 시장 : 약제 클래스별, 투여 경로, 질환 유형, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Angioedema Treatment Market is projected to grow by USD 21.36 billion at a CAGR of 18.60% by 2032.

Angioedema treatment is shifting from reactive emergency management to targeted, mechanism-based care for histaminergic, bradykinin-mediated, hereditary, acquired, and drug-induced disease. Treatment demand is anchored by the clinical need to prevent airway compromise, reduce emergency department utilization, and improve quality of life for patients whose attacks can be unpredictable, painful, and potentially life-threatening.

The strongest growth signals are concentrated in hereditary angioedema treatment, where C1 esterase inhibitor replacement, bradykinin B2 receptor antagonism, plasma kallikrein inhibition, and newer prophylactic biologics and oral therapies have expanded options beyond older androgen-based regimens. Demand is also supported by improved diagnostic awareness, wider availability of C4 and C1-INH testing, specialist referral pathways, and patient preference for home-administered or oral therapies.

Transformative Shifts in the Angioedema Treatment Landscape

The angioedema treatment landscape is being reshaped by precision medicine, faster diagnosis, and a clearer separation between histamine-mediated swelling and bradykinin-mediated disease. This distinction is commercially and clinically important because allergic angioedema typically relies on antihistamines, corticosteroids, and epinephrine when anaphylaxis is suspected, while hereditary angioedema and ACE inhibitor-associated cases require bradykinin-pathway strategies rather than conventional allergy protocols.

Transformative shifts include the rise of long-term prophylaxis, patient-administered rescue therapy, and oral treatment alternatives that reduce dependence on infusion-based care. Payers and providers are increasingly evaluating therapies through attack reduction, time to symptom relief, reduced hospitalization, adherence, safety, and total cost of care, creating opportunities for innovators that can demonstrate durable outcomes in real-world populations.

Cumulative Impact of Artificial Intelligence on Angioedema Care

Artificial intelligence is creating cumulative value across the angioedema care pathway, particularly in earlier recognition of rare hereditary angioedema patterns. AI-enabled clinical decision support can help flag recurrent abdominal pain, swelling without urticaria, family history, low C4 results, or poor response to antihistamines, which are signals that often precede specialist diagnosis.

In drug development and commercialization, AI is improving trial feasibility, patient identification, adverse-event monitoring, and real-world evidence generation. Natural language processing can support pharmacovigilance for biologics and oral kallikrein inhibitors, while predictive analytics can help health systems identify high-risk patients who may benefit from prophylaxis or structured home-treatment plans. These applications strengthen market access when paired with validated clinical oversight, privacy safeguards, and transparent data governance.

Key Regional Insights for Angioedema Treatment

North America remains the most mature angioedema treatment region, led by the United States with strong rare disease reimbursement infrastructure, broad specialist networks, established emergency-care protocols, and early adoption of C1-INH products, bradykinin antagonists, monoclonal antibodies, and oral kallikrein inhibitors. Canada shows steady uptake supported by public and private reimbursement review pathways, though access can vary by province, formulary status, and treatment setting.

Europe is characterized by established hereditary angioedema clinical guidelines, strong academic centers, and structured access across major markets including Germany, France, Italy, Spain, and the United Kingdom. The European Union's centralized regulatory framework supports cross-border evidence standards, while national health technology assessment bodies maintain pricing discipline and require robust outcomes evidence for acute therapy, prophylaxis, and long-term disease control.

Asia-Pacific is expanding as Japan, China, South Korea, Australia, and India improve rare disease recognition and specialist referral capacity. Japan and Australia have relatively advanced access environments, while China and India present long-term treatment potential as diagnostic availability, physician education, and reimbursement pathways develop. Latin America, led by Brazil and Mexico, is progressing through specialty-care adoption but continues to face uneven access, affordability barriers, and differences between public and private systems. The Middle East, particularly GCC countries, benefits from investment in tertiary care, government-funded specialty treatment, and imported innovative medicines, while Africa remains an underpenetrated region where diagnosis, product availability, affordability, and acute-care readiness remain central challenges.

Key Economic Group Insights Across Angioedema Markets

The G7 markets provide the strongest commercial foundation for premium angioedema therapies because of rare disease policy maturity, specialist density, established pharmacovigilance systems, and payer familiarity with high-value biologics and orphan medicines. Within this group, the United States, Germany, Japan, France, Italy, the United Kingdom, and Canada collectively shape clinical adoption patterns, pricing expectations, evidence standards, and real-world outcome requirements for global manufacturers.

The European Union is influential because centralized authorization can support market entry, while individual member states determine reimbursement, prescribing restrictions, budget impact management, and patient access timelines. NATO countries overlap significantly with high-income markets and maintain advanced emergency-care systems, which is important for acute angioedema management, airway-risk protocols, and hospital readiness.

BRICS markets represent long-term volume potential rather than uniform near-term access. China, India, and Brazil are particularly important because of large patient pools and improving rare disease policy frameworks, while Russia and South Africa face more variable availability and reimbursement dynamics. ASEAN markets are heterogeneous, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differing widely in diagnostic capacity, specialist concentration, and specialty drug funding. GCC countries show strong potential for advanced therapies because tertiary hospitals, government-funded care, genetic disease initiatives, and medical tourism strategies support rare disease treatment adoption.

Key Country Insights in Angioedema Treatment

The United States leads global angioedema treatment adoption due to FDA-approved acute and prophylactic options, extensive allergist-immunologist networks, strong patient advocacy activity, and established pathways for home administration. Canada follows with evidence-based reimbursement review and growing use of targeted hereditary angioedema therapies. Mexico and Brazil are the most important Latin American markets, where urban specialty centers support diagnosis and treatment but broader access remains constrained by reimbursement, affordability, and public-system coverage variation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established rare disease systems, clinical guidelines, and specialist-led care pathways. Germany's early access environment and physician autonomy support rapid adoption after approval, while France, Italy, and Spain emphasize negotiated reimbursement and guideline-supported use. The United Kingdom relies on health technology assessment and specialized commissioning to balance clinical value with budget impact. Russia has pockets of specialty access but faces greater variability in product availability, reimbursement consistency, and continuity of supply.

In Asia-Pacific, China and India offer the largest long-term patient opportunities as awareness, diagnostic capacity, and rare disease policy attention improve. Japan and South Korea have advanced healthcare systems and strong regulatory capabilities that support innovative therapies and specialist management. Australia provides a structured reimbursement environment and high clinical awareness in rare disease centers, making it an important regional benchmark for access, outcomes tracking, and patient-centered care.

Actionable Recommendations for Angioedema Industry Leaders

Industry leaders should prioritize differentiated clinical value, especially faster attack relief, lower attack frequency, easier administration, favorable safety, and improved patient-reported outcomes. Products that reduce emergency visits, support self-administration, or offer oral convenience are well positioned as patients and clinicians seek less burdensome treatment models.

Manufacturers should invest in diagnostic education for emergency physicians, allergists, immunologists, gastroenterologists, dermatologists, and primary care providers because delayed recognition remains a major barrier in hereditary and bradykinin-mediated angioedema. Market access teams should build evidence packages around real-world effectiveness, adherence, health economic impact, quality-of-life gains, and reduced acute-care utilization.

Commercial strategies should also be region-specific. Mature markets require strong payer dossiers and comparative value evidence, while emerging markets need physician education, patient identification, local partnerships, and tiered access models. Across all markets, patient support programs, home-treatment training, digital adherence tools, and registry-based evidence can strengthen persistence and outcomes.

Research Methodology

This executive summary is based on a structured review of verified secondary sources, including regulatory approvals, clinical guidelines, peer-reviewed literature, rare disease policy documents, health technology assessment materials, pharmacovigilance resources, and publicly available epidemiology and treatment-access evidence. The analysis emphasizes approved therapies, recognized mechanisms of disease, and established clinical pathways rather than speculative claims.

Market interpretation combines qualitative assessment of regulatory environments, reimbursement dynamics, clinical adoption, regional healthcare infrastructure, emergency-care capacity, and patient access barriers. Insights are triangulated across multiple source categories to support accuracy, consistency, and relevance for stakeholders in pharmaceutical strategy, market access, competitive intelligence, and healthcare investment.

Conclusion

The angioedema treatment market is entering a more advanced phase defined by targeted therapies, better disease classification, expanding prophylaxis, and increasing demand for convenient home-based and oral options. As clinical awareness improves, more patients are expected to move from episodic emergency care toward individualized long-term management based on disease mechanism, attack burden, and patient preference.

Future leadership will depend on evidence-backed differentiation, global access planning, patient-centered support, and credible real-world outcomes. Organizations that align innovation with affordability, earlier diagnosis, safe administration, and measurable clinical benefit will be best positioned to expand access across both mature rare disease markets and emerging healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Angioedema Treatment Market, by Drug Class

• 7.1. Bradykinin Receptor Antagonists
• 7.2. C1 Inhibitors
• 7.3. Kallikrein Inhibitors

8. Angioedema Treatment Market, by Administration Route

• 8.1. Injectable
• 8.2. Oral

9. Angioedema Treatment Market, by Disease Type

• 9.1. Acquired
• 9.2. Hereditary
• 9.3. Idiopathic

10. Angioedema Treatment Market, by End User

• 10.1. Home Care
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Angioedema Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Angioedema Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Angioedema Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Angioedema Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Adverum Biotechnologies, Inc.
• 16.2. Argenx NV
• 16.3. AstraZeneca plc
• 16.4. Attune Pharmaceuticals, Inc.
• 16.5. Aurobindo Pharma Ltd.
• 16.6. Bayer AG
• 16.7. BioCryst Pharmaceuticals, Inc.
• 16.8. Cipla Limited
• 16.9. CSL Behring
• 16.10. Dr. Reddy's Laboratories Ltd.
• 16.11. GlaxoSmithKline plc
• 16.12. HAE Pharma LLC
• 16.13. Intellia Therapeutics, Inc.
• 16.14. Ionis Pharmaceuticals, Inc.
• 16.15. KalVista Pharmaceuticals Ltd.
• 16.16. Merck & Co., Inc.
• 16.17. Novartis AG
• 16.18. Otsuka Pharmaceutical Co., Ltd.
• 16.19. Pfizer Inc.
• 16.20. Pharming Group N.V.
• 16.21. Pharvaris Netherlands B.V.
• 16.22. Sanofi S.A.
• 16.23. Sobi
• 16.24. Takeda Pharmaceutical Company Limited
• 16.25. Teva Pharmaceutical Industries Ltd.